Metastatic Colorectal Cancers Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01163396First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerTreatment
NCT01862003Phase I/II Trial of Antagonism of HER in GI CancerTreatment
NCT01220063RSHF in Colorectal CancerTreatment
NCT01321957Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal CancerTreatment
NCT00418938SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialTreatment
NCT00614393Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)Treatment
NCT02129257´╗┐Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal CancerTreatment
NCT00875771Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsTreatment
NCT00191984A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal CancerTreatment
NCT00254137Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.Treatment
NCT00286130Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal CancerTreatment
NCT00332163Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based TherapyTreatment
NCT00475293Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRCTreatment
NCT00689624Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal CancerTreatment
NCT00792363Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS MutationsTreatment
NCT00827684Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS MutationsTreatment
NCT00891930Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabTreatment
NCT00958386Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)Treatment
NCT01225744Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted TherapyTreatment
NCT01281761Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)Treatment